2009•Unpublished venueRequires access

Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection

Lawrence C. E. Mbuagbaw, James Irlam

Open publisher page 2 citations

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine which NNRTI—EFV or NVP—is more effective in terms of viral load suppression when given in combination with two NRTIs as part of initial ARV combination therapy for HIV infection in adults and children.

About this research paper

What this paper is about

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine which NNRTI—EFV or NVP—is more effective in terms of viral load suppression when given in combination with two NRTIs as part of initial ARV combination therapy for HIV infection in adults and children.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine which NNRTI—EFV or NVP—is more effective in terms of viral load suppression when given in combination with two NRTIs as part of initial ARV combination therapy for HIV infection in adults and children.

Key concepts: Nevirapine, Efavirenz, Medicine, Reverse-transcriptase inhibitor, Nucleoside Reverse Transcriptase Inhibitor, Virology, Human immunodeficiency virus (HIV), Antiretroviral therapy

Related papers

Back to paper searchBrowse research topicsOriginal source
Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection — Research Paper | ScholarLens